Vor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?

Key Points

• Vor Biopharma's stock price fell by 2.9% to $2.35, with a trading volume of approximately 6.5 million shares, significantly lower than its average daily volume.
• HC Wainwright upgraded Vor's rating from "neutral" to "buy", with a target price of $3.00, while other analysts varied in their assessments, resulting in a current consensus rating of "Moderate Buy".
• Institutional investors hold 97.29% of Vor Biopharma's stock, with significant stakes acquired by RA Capital Management and other hedge funds in recent quarters.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report)'s stock price dropped 2.9% during trading on Tuesday . The company traded as low as $2.30 and last traded at $2.35. Approximately 6,526,475 shares traded hands during trading, a decline of 21% from the average daily volume of 8,310,444 shares. The stock had previously closed at $2.42.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. HC Wainwright upgraded Vor Biopharma from a "neutral" rating to a "buy" rating and set a $3.00 target price for the company in a research report on Monday, June 30th. Baird R W cut shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. JMP Securities restated a "market perform" rating and issued a $6.00 target price on shares of Vor Biopharma in a research report on Friday, May 9th. Finally, Jones Trading lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $5.63.

Vor Biopharma Stock Performance

The firm's 50 day moving average price is $1.10 and its two-hundred day moving average price is $0.98. The company has a market cap of $293.66 million, a P/E ratio of -1.42 and a beta of 2.04.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VOR. RA Capital Management L.P. grew its stake in shares of Vor Biopharma by 74.3% in the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock worth $44,007,000 after acquiring an additional 16,897,159 shares in the last quarter. Lynx1 Capital Management LP bought a new stake in shares of Vor Biopharma in the fourth quarter valued at $707,000. Jane Street Group LLC purchased a new position in shares of Vor Biopharma during the 1st quarter valued at $140,000. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma during the first quarter valued at about $100,000. Finally, Trustees of Columbia University in the City of New York bought a new position in Vor Biopharma in the 4th quarter worth approximately $102,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.